Proven immune markers even now protect their relevance for clinical final decision-building in breast most cancers treatment with even prolonged meanings. Estrogen receptor (ER) degree should not only be categorized in optimistic or destructive. Low ER amounts ?10% of labeled cells should be taken care of in another way (LoE 1a/A/AGO++). Tumors wit